Dietary Tomato or Lycopene Do Not Reduce Castration-Resistant Prostate Cancer Progression in a Murine Model.
TRAMP
androgen deprivation therapy
castration-resistant prostate cancer
lycopene
tomato
Journal
The Journal of nutrition
ISSN: 1541-6100
Titre abrégé: J Nutr
Pays: United States
ID NLM: 0404243
Informations de publication
Date de publication:
01 07 2020
01 07 2020
Historique:
received:
21
01
2020
revised:
05
03
2020
accepted:
26
03
2020
pubmed:
6
5
2020
medline:
18
11
2020
entrez:
6
5
2020
Statut:
ppublish
Résumé
Dietary tomato products or lycopene protect against prostate carcinogenesis, but their impact on the emergence of castration-resistant prostate cancer (CRPC) is unknown. We hypothesized that tomato or lycopene products would reduce the emergence of CRPC. Transgenic adenocarcinoma of the mouse prostate (TRAMP) mice were castrated at 12-13 wk and the emergence of CRPC was monitored by ultrasound in each study. In Study 1, TRAMP mice (n = 80) were weaned onto an AIN-93G-based control diet (Con-L, n = 28), a 10% tomato powder diet (TP-L, 10% lyophilized w/w, n = 26), or a control diet followed by a tomato powder diet after castration (TP-Int1, n = 26). In Study 2, TRAMP mice (n = 85) were randomized onto a control diet with placebo beadlets (Con-Int, n = 29), a tomato diet with placebo beadlets (TP-Int2, n = 29), or a control diet with lycopene beadlets (Lyc-Int, n = 27) following castration (aged 12 wk). Tumor incidence and growth were monitored by ultrasound beginning at an age of 10 wk. Mice were euthanized 4 wk after tumor detection or aged 30 wk if no tumor was detected. Tissue weights were compared by ANOVA followed by Dunnett's test. Tumor volumes were compared using generalized linear mixed model regression. Ultrasound estimates for the in vivo tumor volume were strongly correlated with tumor weight at necropsy (R2 = 0.75 and 0.94, P <0.001 for both Studies 1 and 2, respectively). Dietary treatments after castration did not significantly impact cancer incidence, time to tumor detection, or final tumor weight. In contrast to studies of de novo carcinogenesis in multiple preclinical models, tomato components had no significant impact on the emergence of CRPC in the TRAMP model. It is possible that specific mutant subclones of prostate cancer may continue to show some antiproliferative response to tomato components, but further studies are needed to confirm this.
Sections du résumé
BACKGROUND
Dietary tomato products or lycopene protect against prostate carcinogenesis, but their impact on the emergence of castration-resistant prostate cancer (CRPC) is unknown.
OBJECTIVE
We hypothesized that tomato or lycopene products would reduce the emergence of CRPC.
METHODS
Transgenic adenocarcinoma of the mouse prostate (TRAMP) mice were castrated at 12-13 wk and the emergence of CRPC was monitored by ultrasound in each study. In Study 1, TRAMP mice (n = 80) were weaned onto an AIN-93G-based control diet (Con-L, n = 28), a 10% tomato powder diet (TP-L, 10% lyophilized w/w, n = 26), or a control diet followed by a tomato powder diet after castration (TP-Int1, n = 26). In Study 2, TRAMP mice (n = 85) were randomized onto a control diet with placebo beadlets (Con-Int, n = 29), a tomato diet with placebo beadlets (TP-Int2, n = 29), or a control diet with lycopene beadlets (Lyc-Int, n = 27) following castration (aged 12 wk). Tumor incidence and growth were monitored by ultrasound beginning at an age of 10 wk. Mice were euthanized 4 wk after tumor detection or aged 30 wk if no tumor was detected. Tissue weights were compared by ANOVA followed by Dunnett's test. Tumor volumes were compared using generalized linear mixed model regression.
RESULTS
Ultrasound estimates for the in vivo tumor volume were strongly correlated with tumor weight at necropsy (R2 = 0.75 and 0.94, P <0.001 for both Studies 1 and 2, respectively). Dietary treatments after castration did not significantly impact cancer incidence, time to tumor detection, or final tumor weight.
CONCLUSIONS
In contrast to studies of de novo carcinogenesis in multiple preclinical models, tomato components had no significant impact on the emergence of CRPC in the TRAMP model. It is possible that specific mutant subclones of prostate cancer may continue to show some antiproliferative response to tomato components, but further studies are needed to confirm this.
Identifiants
pubmed: 32369574
pii: S0022-3166(22)02239-8
doi: 10.1093/jn/nxaa107
pmc: PMC7330476
doi:
Substances chimiques
Lycopene
SB0N2N0WV6
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
1808-1817Subventions
Organisme : NIBIB NIH HHS
ID : R37 EB002641
Pays : United States
Organisme : NIBIB NIH HHS
ID : T32 EB019944
Pays : United States
Informations de copyright
Copyright © The Author(s) on behalf of the American Society for Nutrition 2020.
Références
Mol Nutr Food Res. 2015 Apr;59(4):658-69
pubmed: 25620547
Biochim Biophys Acta. 2005 May 30;1740(2):202-5
pubmed: 15949687
Cancer Prev Res (Phila). 2014 Dec;7(12):1228-39
pubmed: 25315431
Cancer Prev Res (Phila). 2017 Feb;10(2):161-169
pubmed: 27807077
Cancer Treat Rev. 2015 Jul;41(7):588-97
pubmed: 25981454
J Nutr. 1999 Dec;129(12):2271-7
pubmed: 10573562
Neoplasia. 2011 Feb;13(2):108-19
pubmed: 21403837
Cancer Res. 1997 Nov 1;57(21):4687-91
pubmed: 9354422
Cell. 2015 May 21;161(5):1215-1228
pubmed: 26000489
J Natl Cancer Inst. 2019 Dec 1;111(12):1279-1297
pubmed: 31145458
J Nutr Biochem. 2013 Oct;24(10):1724-34
pubmed: 23746934
Am J Clin Nutr. 2015 Dec;102(6):1436-49
pubmed: 26561629
Urology. 2007 Feb;69(2):289-94
pubmed: 17320666
Am J Epidemiol. 2002 Jun 1;155(11):1023-32
pubmed: 12034581
J Nutr. 2019 Mar 1;149(3):381-397
pubmed: 30801647
Cancer Causes Control. 2011 Nov;22(11):1483-95
pubmed: 21800039
Cancer Epidemiol Biomarkers Prev. 2001 Aug;10(8):861-8
pubmed: 11489752
Nutr Cancer. 2013;65(7):1076-85
pubmed: 24053141
Adv Nutr. 2016 May 16;7(3):438-44
pubmed: 27184271
Am J Clin Nutr. 2010 Jun;91(6):1716-24
pubmed: 20392890
J Am Med Assoc. 1946 Jun 15;131:576-81
pubmed: 20986021
J Urol. 2002 Jul;168(1):9-12
pubmed: 12050481
Nutrients. 2019 Mar 15;11(3):
pubmed: 30875962
Nutr Cancer. 2007;59(1):1-7
pubmed: 17927495
J Natl Cancer Inst. 2001 Dec 19;93(24):1872-9
pubmed: 11752012
Am J Clin Nutr. 2015 Nov;102(5):1142-57
pubmed: 26447150
Prostate Cancer Prostatic Dis. 2018 Sep;21(3):319-336
pubmed: 29317772
Oncotarget. 2017 Jan 10;8(2):3724-3745
pubmed: 27741508
Lancet Oncol. 2014 May;15(6):543-4
pubmed: 24739898
Mol Cancer Res. 2008 Nov;6(11):1691-701
pubmed: 19010817
Prostate. 2009 Jul 1;69(10):1034-44
pubmed: 19343735
Br J Nutr. 2015 Aug 28;114(4):596-607
pubmed: 26202168
J Natl Cancer Inst. 2014 Feb;106(2):djt430
pubmed: 24463248
Cancer Prev Res (Phila). 2013 Jun;6(6):548-57
pubmed: 23592738
FASEB J. 2008 Mar;22(3):659-61
pubmed: 17942826
Annu Rev Nutr. 2012 Aug 21;32:369-90
pubmed: 22524186
Free Radic Biol Med. 2015 Jun;83:238-44
pubmed: 25772008
Prostate. 2003 May 15;55(3):219-37
pubmed: 12692788
J Natl Cancer Inst. 2003 Nov 5;95(21):1578-86
pubmed: 14600090
Nat Commun. 2018 Sep 6;9(1):3600
pubmed: 30190514
Cancer Res. 2005 Jul 15;65(14):6337-45
pubmed: 16024636
Cancer Epidemiol Biomarkers Prev. 2013 Dec;22(12):2145-7
pubmed: 24130222
BJU Int. 2003 Sep;92(4):375-8; discussion 378
pubmed: 12930422
Nutr Res. 2015 Oct;35(10):882-890
pubmed: 26255194
PLoS One. 2017 Apr 28;12(4):e0176124
pubmed: 28453517
Toxicol Pathol. 2012;40(1):5-17
pubmed: 22021166
J Nutr. 2019 Jan 1;149(1):26-35
pubmed: 30476157
J Urol. 2009 Mar;181(3):1098-103
pubmed: 19150092
Nutr Cancer. 2003;47(1):40-7
pubmed: 14769536
J Nutr. 2005 Feb;135(2):287-90
pubmed: 15671228
Ann Behav Med. 2018 Apr 19;52(5):412-428
pubmed: 29684136
Cancer Epidemiol Biomarkers Prev. 1996 Oct;5(10):823-33
pubmed: 8896894
J Agric Food Chem. 2011 May 25;59(10):5335-41
pubmed: 21449543
Mol Nutr Food Res. 2011 Apr;55(4):606-12
pubmed: 21462328
Prostate Cancer Prostatic Dis. 2017 Dec;20(4):361-377
pubmed: 28440323
Cancer Res. 1999 Oct 1;59(19):5030-6
pubmed: 10519419